TPCW
CERE

TD Private Client Wealth’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

TD Private Client Wealth’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-78
Closed -$3.19K – 1302
2024
Q2 		$3.19K Buy
+78
New +$3.25K ﹤0.01% 1113

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

TD Private Client Wealth's CERE Position: Q3 2024 in Review

TD Private Client Wealth sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 78 shares — an estimated $3.19K sold.

TD Private Client Wealth first reported a position in CERE in Q2 2024 and held it in 1 quarter. The position peaked at $3.19K in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • TD Private Client Wealth reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • TD Private Client Wealth sold 78 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $3.19K.
  • TD Private Client Wealth first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2024 and held it in 1 quarter.
  • TD Private Client Wealth's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $3.19K in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on TD Private Client Wealth's 13F filing for Q3 2024, filed 18 Nov 2024.